Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Supply continues to cause headaches for radiopharmaceutical developers.
Meanwhile, Lilly gets in on the next-gen KRAS action.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
ASCO is fast approaching, but in the meantime Olema will have an important readout.